{"id":323683,"date":"2026-10-22T12:35:35","date_gmt":"2026-10-22T07:05:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=323683"},"modified":"2026-10-22T12:35:35","modified_gmt":"2026-10-22T07:05:35","slug":"oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/","title":{"rendered":"3 Oncology Generics, Acute Therapy Franchise and Pain and Anti-Malarial Brands Stocks With a Strong Future Roadmap: Natco Pharma, Alkem Laboratories and Ipca Laboratories"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Natco Pharma, Alkem Laboratories and Ipca Laboratories: ROE of 14.2% to 16.7% and FY22 to FY26 revenue CAGR of 9.1% to 21.0%. Prices as of 21 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three complex generic and pain care stocks to watch are Natco Pharma, Alkem Laboratories and Ipca Laboratories. Their return on equity ranges from 14.2% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 21.0%. Alkem Laboratories has the highest return on equity at 16.7%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Complex generic and pain care stocks let investors follow companies that combine hard-to-copy generics with well-known domestic brands. Natco Pharma, Alkem Laboratories and Ipca Laboratories cover oncology generics, an acute therapy franchise, and pain and anti-malarial brands.<\/p>\n<p>This list covers three complex generic and pain care stocks with complete current figures: Natco Pharma, Alkem Laboratories and Ipca Laboratories. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#What_Are_Complex_Generic_and_Pain_Care_Stocks\" title=\"What Are Complex Generic and Pain Care Stocks?\">What Are Complex Generic and Pain Care Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Complex_Generic_and_Pain_Care_Stocks_at_a_Glance\" title=\"Complex Generic and Pain Care Stocks at a Glance\">Complex Generic and Pain Care Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Why_Do_Complex_Generic_and_Pain_Care_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Complex Generic and Pain Care Stocks Have a Strong Roadmap in India?\">Why Do Complex Generic and Pain Care Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Why_Natco_Pharma_Features_Among_These_Complex_Generic_and_Pain_Care_Stocks\" title=\"Why Natco Pharma Features Among These Complex Generic and Pain Care Stocks\">Why Natco Pharma Features Among These Complex Generic and Pain Care Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Why_Alkem_Laboratories_Features_Among_These_Complex_Generic_and_Pain_Care_Stocks\" title=\"Why Alkem Laboratories Features Among These Complex Generic and Pain Care Stocks\">Why Alkem Laboratories Features Among These Complex Generic and Pain Care Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Why_Ipca_Laboratories_Features_Among_These_Complex_Generic_and_Pain_Care_Stocks\" title=\"Why Ipca Laboratories Features Among These Complex Generic and Pain Care Stocks\">Why Ipca Laboratories Features Among These Complex Generic and Pain Care Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Natco_Pharma_vs_Alkem_Laboratories_vs_Ipca_Laboratories_on_Key_Financials\" title=\"Natco Pharma vs Alkem Laboratories vs Ipca Laboratories on Key Financials\">Natco Pharma vs Alkem Laboratories vs Ipca Laboratories on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Key_Risks_to_Check_Before_Investing_in_Complex_Generic_and_Pain_Care_Stocks\" title=\"Key Risks to Check Before Investing in Complex Generic and Pain Care Stocks\">Key Risks to Check Before Investing in Complex Generic and Pain Care Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Final_Thoughts_on_Complex_Generic_and_Pain_Care_Stocks\" title=\"Final Thoughts on Complex Generic and Pain Care Stocks\">Final Thoughts on Complex Generic and Pain Care Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#What_are_complex_generic_and_pain_care_stocks\" title=\"What are complex generic and pain care stocks?\">What are complex generic and pain care stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Which_complex_generic_and_pain_care_stocks_are_covered_in_this_list\" title=\"Which complex generic and pain care stocks are covered in this list?\">Which complex generic and pain care stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Why_do_complex_generic_and_pain_care_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do complex generic and pain care stocks have a strong future roadmap in India?\">Why do complex generic and pain care stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#How_has_Natco_Pharma_performed_financially\" title=\"How has Natco Pharma performed financially?\">How has Natco Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#How_has_Alkem_Laboratories_performed_financially\" title=\"How has Alkem Laboratories performed financially?\">How has Alkem Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#How_has_Ipca_Laboratories_performed_financially\" title=\"How has Ipca Laboratories performed financially?\">How has Ipca Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#What_risks_should_investors_check_before_buying_complex_generic_and_pain_care_stocks\" title=\"What risks should investors check before buying complex generic and pain care stocks?\">What risks should investors check before buying complex generic and pain care stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands-stocks-roadmap-outpost-list\/#Is_this_list_of_complex_generic_and_pain_care_stocks_investment_advice\" title=\"Is this list of complex generic and pain care stocks investment advice?\">Is this list of complex generic and pain care stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Complex_Generic_and_Pain_Care_Stocks\"><\/span><strong>What Are Complex Generic and Pain Care Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Complex generic and pain care stocks are listed pharmaceutical companies that sell complex generics abroad and leading brands in acute therapies at home. Their earnings depend on approvals, launches and prescription trends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Complex_Generic_and_Pain_Care_Stocks_at_a_Glance\"><\/span><strong>Complex Generic and Pain Care Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">784.45<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/alkem\/alkem-laboratories-ltd-share-price-today\">Alkem Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,015<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59,723<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.15<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ipcalab\/ipca-laboratories-ltd-share-price-today\">Ipca Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,918.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">46,050<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.10<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing complex generic and pain care stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Complex_Generic_and_Pain_Care_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Complex Generic and Pain Care Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Complex generic and pain care stocks have a strong roadmap in India because rising demand for acute care at home and for complex generics abroad supports steady growth for established players.<\/p>\n<ul>\n<li><strong>Complex products.<\/strong> Hard-to-make generics face fewer competitors.<\/li>\n<li><strong>Acute care demand.<\/strong> Brands in pain and infection care see recurring prescriptions.<\/li>\n<li><strong>Wider access.<\/strong> Better reach brings medicines to smaller towns.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Natco_Pharma_Features_Among_These_Complex_Generic_and_Pain_Care_Stocks\"><\/span><strong>Why Natco Pharma Features Among These Complex Generic and Pain Care Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the complex generic and pain care stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.<\/p>\n<p>Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.<\/p>\n<p>The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the timing of key product launches in the US and the contribution from new drug approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Alkem_Laboratories_Features_Among_These_Complex_Generic_and_Pain_Care_Stocks\"><\/span><strong>Why Alkem Laboratories Features Among These Complex Generic and Pain Care Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the oncology generic shares on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.<\/p>\n<p>In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%.<\/p>\n<p>Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P\/E of 27.1, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> Alkem&#8217;s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ipca_Laboratories_Features_Among_These_Complex_Generic_and_Pain_Care_Stocks\"><\/span><strong>Why Ipca Laboratories Features Among These Complex Generic and Pain Care Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.<\/p>\n<p>The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_vs_Alkem_Laboratories_vs_Ipca_Laboratories_on_Key_Financials\"><\/span><strong>Natco Pharma vs Alkem Laboratories vs Ipca Laboratories on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three complex generic and pain care stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Natco Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,376<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,372<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">31.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Alkem Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10,797<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,296<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,353<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ipca Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,896<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,821<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,191<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Alkem Laboratories posts the highest return on equity in this group at 16.7%. Alkem Laboratories has the largest FY26 revenue at Rs 15,296 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with complex generic and pain care stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Complex_Generic_and_Pain_Care_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Complex Generic and Pain Care Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these complex generic and pain care stocks, the main points are: Long-term oncology generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Pricing rules.<\/strong> Price controls can limit the pace of growth for some medicines.<\/li>\n<li><strong>Approval timelines.<\/strong> Launches depend on regulatory decisions that can shift.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter complex generic and pain care stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Complex_Generic_and_Pain_Care_Stocks\"><\/span><strong>Final Thoughts on Complex Generic and Pain Care Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Complex generic and pain care stocks reward investors who follow approvals, launches and prescription trends together. Natco Pharma, Alkem Laboratories and Ipca Laboratories each bring a strong franchise. Based on the 21 October 2026 close, Natco Pharma trades at Rs 784.45, Alkem Laboratories at Rs 5,015 and Ipca Laboratories at Rs 1,918.9.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track complex generic and pain care stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_complex_generic_and_pain_care_stocks\"><\/span><strong>What are complex generic and pain care stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Complex generic and pain care stocks are listed pharmaceutical companies that sell complex generics abroad and leading brands in acute therapies at home. Their earnings depend on approvals, launches and prescription trends. This list looks at three of them, Natco Pharma, Alkem Laboratories and Ipca Laboratories, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_complex_generic_and_pain_care_stocks_are_covered_in_this_list\"><\/span><strong>Which complex generic and pain care stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Natco Pharma, Alkem Laboratories and Ipca Laboratories. Based on the 21 October 2026 close, Natco Pharma traded at Rs 784.45, Alkem Laboratories at Rs 5,015 and Ipca Laboratories at Rs 1,918.9. Their return on equity ranges from 14.2% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 21.0%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_complex_generic_and_pain_care_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do complex generic and pain care stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Complex generic and pain care stocks have a strong roadmap in India because rising demand for acute care at home and for complex generics abroad supports steady growth for established players. The main drivers are as follows. Complex products. Hard-to-make generics face fewer competitors. Acute care demand. Brands in pain and infection care see recurring prescriptions. Wider access. Better reach brings medicines to smaller towns. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Natco_Pharma_performed_financially\"><\/span><strong>How has Natco Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Alkem_Laboratories_performed_financially\"><\/span><strong>How has Alkem Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P\/E of 27.1, below the industry P\/E of 36.0. Looking ahead, alkem&#8217;s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ipca_Laboratories_performed_financially\"><\/span><strong>How has Ipca Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_complex_generic_and_pain_care_stocks\"><\/span><strong>What risks should investors check before buying complex generic and pain care stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying complex generic and pain care stocks. Pricing rules. Price controls can limit the pace of growth for some medicines. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_complex_generic_and_pain_care_stocks_investment_advice\"><\/span><strong>Is this list of complex generic and pain care stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are complex generic and pain care stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Complex generic and pain care stocks are listed pharmaceutical companies that sell complex generics abroad and leading brands in acute therapies at home. Their earnings depend on approvals, launches and prescription trends. This list looks at three of them, Natco Pharma, Alkem Laboratories and Ipca Laboratories, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which complex generic and pain care stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Natco Pharma, Alkem Laboratories and Ipca Laboratories. Based on the 21 October 2026 close, Natco Pharma traded at Rs 784.45, Alkem Laboratories at Rs 5,015 and Ipca Laboratories at Rs 1,918.9. Their return on equity ranges from 14.2% to 16.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.1% to 21.0%.\"}},{\"@type\":\"Question\",\"name\":\"Why do complex generic and pain care stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Complex generic and pain care stocks have a strong roadmap in India because rising demand for acute care at home and for complex generics abroad supports steady growth for established players. The main drivers are as follows. Complex products. Hard-to-make generics face fewer competitors. Acute care demand. Brands in pain and infection care see recurring prescriptions. Wider access. Better reach brings medicines to smaller towns. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Natco Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Alkem Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P\/E of 27.1, below the industry P\/E of 36.0. Looking ahead, alkem's strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Ipca Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying complex generic and pain care stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying complex generic and pain care stocks. Pricing rules. Price controls can limit the pace of growth for some medicines. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of complex generic and pain care stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Complex Generic and Pain Care Stocks with a strong future roadmap: Natco Pharma, Alkem Laboratories and Ipca Laboratories. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.<\/p>\n","protected":false},"author":38,"featured_media":323680,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[10617,3803,14739,13964,14124,14740,14741],"class_list":["post-323683","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-alkem-laboratories","tag-best-stocks","tag-complex-generic-and-pain-care-stocks","tag-ipca-laboratories","tag-natco-pharma","tag-oncology-generic-shares","tag-pain-management-brand-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["323680"],"rank_math_title":["Complex Generic and Pain Care Stocks to Watch"],"rank_math_description":["Compare 3 complex generic and pain care stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 21 Oct 2026."],"rank_math_focus_keyword":["complex generic and pain care stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-oncology-generics-acute-therapy-franchise-and-pain-and-anti-malarial-brands.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=323683"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323683\/revisions"}],"predecessor-version":[{"id":323684,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/323683\/revisions\/323684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/323680"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=323683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=323683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=323683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}